Compare III & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | III | ALLO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 252.9M |
| IPO Year | 2007 | 2018 |
| Metric | III | ALLO |
|---|---|---|
| Price | $5.34 | $1.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $7.00 | ★ $8.67 |
| AVG Volume (30 Days) | 285.5K | ★ 2.4M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $241,289,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.84 | $100.00 |
| P/E Ratio | $28.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.95 | $0.86 |
| 52 Week High | $6.45 | $3.78 |
| Indicator | III | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 67.33 |
| Support Level | $4.98 | $1.20 |
| Resistance Level | $5.25 | $1.35 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 84.44 | 89.71 |
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.